Drug intelligence / Profile preview

gemcitabine + nab-paclitaxel + iparomlimab + tuvorilimab

Development stage: Unknown
Lead developer: Qilu Pharmaceutical
Modality: Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

This combination therapy consists of the chemotherapy agents gemcitabine and nab-paclitaxel (the AG regimen) administered alongside two immune checkpoint inhibitors: iparomlimab (AK102), an anti-CTLA-4 monoclonal antibody, and tuvorilimab (AK127), an anti-TIGIT monoclonal antibody. The regimen is being evaluated in a Phase II clinical trial sponsored by Xinhua Hospital (Shanghai Jiao Tong University School of Medicine) for the treatment of advanced unresectable gallbladder cancer. The combination aims to enhance anti-tumor immune responses by simultaneously targeting the CTLA-4 and TIGIT pathways while utilizing the cytotoxic effects of chemotherapy to promote immunogenic cell death and improve surgical conversion rates. Both iparomlimab and tuvorilimab were developed by Akeso Bio.

Other names: Iparomlimab and TuvorilimabGemcitabine plus Nab-Paclitaxel in combination with Iparomlimab and Tuvorilimab

Targets

CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)TUBB (Tubulin (alpha and beta subunits))PDCD1 (Programmed cell death protein 1 receptor)RNR (Ribonucleotide reductase)

Beyond the preview

Go deeper on gemcitabine + nab-paclitaxel + iparomlimab + tuvorilimab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on gemcitabine + nab-paclitaxel + iparomlimab + tuvorilimab.

Explore the full profile